Search

Ocular Therapeutix Inc

Suletud

SektorTervishoid

6.49 -1.82

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

6.41

Max

6.54

Põhinäitajad

By Trading Economics

Sissetulek

9.8M

-79M

Müük

2.7M

13M

Aktsiakasum

-0.35

Kasumimarginaal

-584.512

Töötajad

325

EBITDA

10M

-74M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+271.15% upside

Dividendid

By Acuity

Järgmine tulemuste avaldamine

3. nov 2026

Turustatistika

By TradingEconomics

Turukapital

-510M

1.4B

Eelmine avamishind

8.31

Eelmine sulgemishind

6.49

Ocular Therapeutix Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

23. okt 2026, 20:08 UTC

Ocular Therapeutix Inc shares fell amid a broader market decline, rising oil prices, and weak consumer sentiment reflected in October's University of Michigan reading.

21. okt 2026, 20:07 UTC

Ocular Therapeutix Inc shares are declining, having sharply fallen after an early gain, and are currently trading below their 20-day moving average.

20. okt 2026, 20:02 UTC

News
Social Media

Piper Sandler projects Ocular Therapeutix could reach $1.3 billion in revenue by 2030, while Bank of America sets a price target of $27.

19. okt 2026, 20:02 UTC

Social Media
News

Bank of America sets a price target of $27 for Ocular Therapeutix, citing advantages of its drug Axpaxli and an upcoming NDA filing in Q4.

16. okt 2026, 20:02 UTC

Ocular Therapeutix Inc shares fell sharply, facing significant volatility and trading near the lower end of its one-month range and below its 20-day moving average.

15. okt 2026, 19:46 UTC

Social Media

Ocular Therapeutix's investigational product AXPAXLI (OTX-TKI) could achieve $3.3 billion in sales by 2035, according to UBS, surpassing previous estimates.

14. okt 2026, 23:11 UTC

Ocular Therapeutix Inc. is advancing modestly in after-market trading following Wednesday's close.

13. okt 2026, 19:52 UTC

Social Media

Ocular Therapeutix Inc is declining amid market weakness, despite a Buy rating from Bank of America with a price target of $27 and an upcoming NDA filing.

12. okt 2026, 20:06 UTC

Social Media
News

Ocular Therapeutix gains traction after UBS initiated coverage with a Buy rating and a price target of $14, projecting sales for Axpaxli to reach $3.3 billion by 2035.

9. okt 2026, 20:07 UTC

Ocular Therapeutix Inc shares are advancing in Friday's trading session, showing modest gains since Thursday's close despite earlier pulling back from a midday high.

8. okt 2026, 22:15 UTC

Ocular Therapeutix Inc shares are trading modestly lower in after-market hours, having reversed from an early gain and remaining below their 20-day moving average.

7. okt 2026, 23:35 UTC

Ocular Therapeutix Inc is advancing in after-market trading, showing a notable increase since Wednesday's close despite remaining below its 20-day moving average.

6. okt 2026, 22:55 UTC

Ocular Therapeutix Inc. traded modestly higher in after-market hours on Tuesday, recovering from an early dip despite a significant decline over the past month.

5. okt 2026, 23:10 UTC

Ocular Therapeutix Inc's shares declined during after-market hours on Monday, following fluctuations earlier in the session and trading below its 20-day moving average.

2. okt 2026, 23:05 UTC

Ocular Therapeutix Inc is trading higher in after-market hours, reflecting a notable upward trajectory following three consecutive lower finishes.

1. okt 2026, 23:06 UTC

Ocular Therapeutix Inc is trading higher in after-market hours following a modest decline from its earlier high reached after the market closed.

30. sept 2026, 23:35 UTC

Ocular Therapeutix Inc. is trading modestly higher in after-market hours, continuing an upward trend since Wednesday's close despite recent declines.

29. sept 2026, 23:10 UTC

Ocular Therapeutix Inc. is trading higher in after-market hours, with a cumulative return of 0.76% after peaking at 1.51% following Tuesday's close.

28. sept 2026, 23:01 UTC

Ocular Therapeutix Inc is trading higher in after-market hours, rebounding from an earlier session dip despite being below its 20-day moving average.

25. sept 2026, 20:07 UTC

Ocular Therapeutix Inc shares fell sharply, marking the fourth consecutive session of lower closes and remaining well below the 20-day moving average.

24. sept 2026, 20:07 UTC

News

Ocular Therapeutix Inc shares fell sharply, despite earlier gains, as the stock trades near the low end of its one-month range ahead of a presentation today.

23. sept 2026, 20:02 UTC

Ocular Therapeutix Inc shares fell sharply, breaking a trend of higher daily closes since Tuesday, indicating a divergence from recent upward momentum.

22. sept 2026, 20:07 UTC

Ocular Therapeutix Inc is advancing sharply during Tuesday's trading session, reflecting overall market strength, despite pulling back from an earlier peak.

21. sept 2026, 23:10 UTC

Ocular Therapeutix Inc saw a modest increase in after-market trading, gaining ground since Monday's close, despite remaining below its 20-day moving average.

18. sept 2026, 23:25 UTC

Ocular Therapeutix Inc is trading higher in after-market hours, rising from a low post-close and currently above Friday's close but below its 20-day moving average.

17. sept 2026, 20:07 UTC

Ocular Therapeutix Inc is advancing, maintaining gains from Wednesday, despite earlier pulling back from a session high while remaining below its 20-day moving average.

16. sept 2026, 20:10 UTC

Event
Social Media

Ocular Therapeutix Inc shares fell sharply despite positive social media sentiment about its NDA filing for Axpaxli and recent FDA discussions.

15. sept 2026, 22:02 UTC

Event

Ocular Therapeutix Inc. plans to submit its New Drug Application by Q4 2026, but shares are lower in after-market hours amid broader economic concerns.

14. sept 2026, 19:17 UTC

Ocular Therapeutix Inc is trading higher during Monday's session, having gained since Friday's close, despite a negative broader market sentiment.

11. sept 2026, 23:51 UTC

Ocular Therapeutix Inc shares are higher in after-market hours, supported by improved fiscal management reflected in a narrower-than-expected budget deficit of $167 billion for August.

Võrdlus sarnastega

Hinnamuutus

Ocular Therapeutix Inc Prognoos

Hinnasiht

By TipRanks

271.15% tõus

12 kuu keskmine prognoos

Keskmine 24.125 USD  271.15%

Kõrge 31 USD

Madal 14 USD

Põhineb 9 Wall Streeti analüütiku instrumendi Ocular Therapeutix Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

9 ratings

9

Osta

0

Hoia

0

Müü

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Ocular Therapeutix Inc

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
help-icon Live chat